What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Cancer
His scientific interests lie mostly in Immunology, CD8, Antigen, Cytotoxic T cell and T cell.
His study in Immunotherapy, Chimeric antigen receptor, Adoptive cell transfer, CTL* and Cytokine release syndrome is done as part of Immunology.
His work focuses on many connections between CD8 and other disciplines, such as Immunity, that overlap with his field of interest in FOXP3, Cytokine, Interleukin 15 and Herpesviridae.
His Antigen research includes themes of Immune system and T-cell receptor.
His work investigates the relationship between Cytotoxic T cell and topics such as Virology that intersect with problems in In vivo and Genetic enhancement.
His T cell research incorporates elements of Autoimmunity, Computational biology and B cell.
His most cited work include:
- Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor (1681 citations)
- Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells (1160 citations)
- Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells (1160 citations)
What are the main themes of his work throughout his whole career to date?
Stanley R. Riddell mainly focuses on Immunology, Antigen, Cytotoxic T cell, T cell and CD8.
His research on Immunology often connects related topics like Transplantation.
His Antigen study integrates concerns from other disciplines, such as Cancer research, Chimeric antigen receptor and T-cell receptor.
The study incorporates disciplines such as Molecular biology and Virology in addition to Cytotoxic T cell.
His studies in CD8 integrate themes in fields like Cell and Immunity.
His research investigates the connection between Immunotherapy and topics such as Cyclophosphamide that intersect with issues in Oncology.
He most often published in these fields:
- Immunology (84.32%)
- Antigen (56.36%)
- Cytotoxic T cell (54.03%)
What were the highlights of his more recent work (between 2017-2021)?
- Immunotherapy (42.58%)
- Cancer research (32.84%)
- Antigen (56.36%)
In recent papers he was focusing on the following fields of study:
Immunotherapy, Cancer research, Antigen, Chimeric antigen receptor and Internal medicine are his primary areas of study.
His Immunotherapy study results in a more complete grasp of Immunology.
His Cancer research study incorporates themes from Cancer and T cell, CD8, Immune system, CD19.
His CD8 research includes themes of Cytotoxic T cell and Cell.
His Antigen research incorporates themes from In vivo, Tumor microenvironment, Tumor Escape, Adoptive cell transfer and Multiple myeloma.
His studies deal with areas such as Cytokine, Antibody, B cell, Receptor and Cell biology as well as Chimeric antigen receptor.
Between 2017 and 2021, his most popular works were:
- Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. (150 citations)
- Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. (150 citations)
- Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. (134 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
